Clinical Characteristics of Asthma and COPD Overlap for Patients With Asthma and COPD in Hong Kong

NCT03272932 | Active Not Recruiting

• 1 other identifier: CCUHK_Resp_ACOS_v1(5Apr2017)
• Study Type: observational
• Target: 1,600
• Locations: 1 country
• Sites: 1

Brief Summary

This study is to assess the prevalence of Asthma COPD Overlap in subjects with diagnosed asthma and chronic obstructive pulmonary disease (COPD). The subsequent morbidity and mortality of subjects will be followed up for 3 years.

Conditions

Asthma; COPD

Outcome Measures

Primary Outcomes (1)

• Percentage of prevalence of Asthma COPD overlap among the asthma and COPD subjects.

  To determine the proportion and clinical characteristics of patients with ACO as defined by the joint GINA and GOLD recommendation amongst diagnosed COPD and asthma patients seen at the out-patient clinics. (Assessment: % of subjects with ACO among patients with asthma and COPD respectively)

  3 years

Secondary Outcomes (6)

• Percentage of patient with treatment that is different from the guidelines recommendation

  3 years

• The percentages of patients on various medications (e.g. inhaled steroid, LABA, LAMA)

  3 years

• The pecentages of patients receiving different symptoms control assessments (e.g. use of Asthma control test, use of COPD assessment test)

  3 years

• Percentages of subjects with morbidity (e.g. congestive heart failure)

  3 years

• Percentages of subjects with mortality

  3 years

Interventions

No intervention OTHER

No intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Subjects with asthma or COPD

You may qualify if:

• Subjects must fulfil all of the following criteria:
• All patients with confirmed diagnosis of COPD (post-bronchodilator FEV1/FVC\<0.7 based on the medical records) 1 or asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 6
• Aged \>40 years old
• Signed written informed consent to participate in the study

You may not qualify if:

• Patients currently with acute exacerbation of COPD by GOLD definition (any worsening of a patient's respiratory symptoms that is beyond normal day-to-day variations and requires a change in medication) 1 or acute exacerbation of asthma by GINA guideline. 6
• Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment
• Patients currently diagnosed with pneumonia and acute bronchitis
• Patients currently randomized in other clinical studies

Sponsors & Collaborators

• Chinese University of Hong Kong: lead

Study Sites (1)

Prince of Wales Hospital

Hong Kong, Hong Kong

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood will be stored for future genetic studies. As there is currently no good biomarker or genetic tests that can identify the cause or suggest the diagnosis of Asthma COPD overlap, this study would like to explore into this.

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Asthma

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bronchial Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Fanny Ko, MD

  Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Honorary Clinical Associate Professor

Study Record Dates

• First Submitted: September 1, 2017
• First Posted: September 6, 2017
• Study Start: September 15, 2017
• Primary Completion: December 30, 2025
• Study Completion (Estimated): December 30, 2026
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)